Clinical Scorecard: Alterable Risk Factors Influencing the Advancement of Chronic Kidney Disease

At a Glance

Key Highlights

• CKD progression is strongly influenced by modifiable lifestyle and metabolic factors such as hypertension, diabetes, obesity, dietary sodium intake, and metabolic dysregulation.
• Emerging biomarkers integrating inflammatory, metabolic, and immune indices (e.g., serum uric acid-to-albumin ratio, Ins60/ApoA ratio, complement C3, systemic immuno-inflammatory index) offer potential for early diagnosis and risk stratification.
• Maintaining stable haemoglobin and haematocrit levels in stage 3–4 CKD patients is associated with better clinical outcomes, emphasizing the importance of monitoring hematologic parameters.

Guideline-Based Recommendations

Diagnosis

• Utilize composite biomarkers reflecting inflammation, metabolism, and immune activation for early CKD risk stratification.
• Incorporate assessment of dietary and metabolic risk factors such as sodium intake, triglyceride/HDL cholesterol ratio, and insulin resistance indices.

Management

• Implement early and individualized interventions targeting modifiable risk factors including hypertension, diabetes control, dietary modifications, and metabolic regulation.
• Integrate public health policies with personalized cardiometabolic risk management to reduce CKD burden.
• Monitor and manage systemic inflammation and metabolic dysfunction to slow CKD progression.

Monitoring & Follow-up

• Regularly assess inflammatory and metabolic indices (e.g., NLR, PLR, GLR, SII) alongside traditional renal function tests.
• Track haemoglobin and haematocrit stability in patients with advanced CKD stages.
• Evaluate dietary patterns and cardiometabolic risk factors continuously to adjust management plans.

Risks

• High sodium intake and poor dietary habits increase CKD progression risk and associated cardiovascular morbidity.
• Uncontrolled hypertension and type 2 diabetes exacerbate renal dysfunction through metabolic and inflammatory pathways.
• Systemic inflammation and immune dysregulation contribute to worse CKD prognosis and increased mortality.

Patient & Prescribing Data

Patients with CKD across diverse socio-demographic backgrounds, including those with hypertension and type 2 diabetes.

Targeted interventions addressing modifiable metabolic and inflammatory risk factors can potentially slow CKD progression; personalized treatment guided by integrated biomarker indices may improve outcomes.

Clinical Best Practices

• Early identification of modifiable risk factors such as hypertension, diabetes, and dietary sodium intake is critical.
• Use integrated biomarker panels combining inflammatory, metabolic, and immune parameters for risk stratification.
• Maintain stable haemoglobin and haematocrit levels in advanced CKD to improve prognosis.
• Adopt a multidisciplinary approach combining public health strategies with individualized patient management.
• Focus on systemic metabolic and inflammatory dysfunction beyond renal parameters to address CKD as a systemic disorder.

References

• Li et al. - Global Burden of Disease data analysis on CKD
• Lu et al. - Impact of high sodium intake on CKD burden
• Huang et al. - Dietary factors and hypertension-related CKD burden
• Wang et al. - Hypertension and CKD progression studies
• Du et al. - Serum uric acid-to-albumin ratio as biomarker
• Sun et al. - Ins60/ApoA ratio and diabetic kidney disease
• Fu et al. - Complement C3 and vascular calcification in CKD
• Hou et al. - Inflammatory and metabolic indices in haemodialysis patients
• Ma et al. - Systemic immuno-inflammatory index and mortality in CKD